MX2010002003A - Metodo de produccion. - Google Patents

Metodo de produccion.

Info

Publication number
MX2010002003A
MX2010002003A MX2010002003A MX2010002003A MX2010002003A MX 2010002003 A MX2010002003 A MX 2010002003A MX 2010002003 A MX2010002003 A MX 2010002003A MX 2010002003 A MX2010002003 A MX 2010002003A MX 2010002003 A MX2010002003 A MX 2010002003A
Authority
MX
Mexico
Prior art keywords
methods
amplification
selection
cell lines
frames
Prior art date
Application number
MX2010002003A
Other languages
English (en)
Inventor
Mark Uden
Ekaterini Kotsopoulou
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2010002003A publication Critical patent/MX2010002003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator

Abstract

La presente invención proporciona métodos para reducir los niveles de presión elegibles titulables requeridos, la cantidad de ciclos de amplificación, y el tiempo que tarda generar las líneas celulares de expresión de proteína alterando los codones de las fases de lectura abiertas deseadas. A través del uso de la adaptación al codón para este propósito, los métodos de la invención proporcionan constantemente suficientes producciones en períodos de tiempo más rápidos que ahorran muchas semanas de actividades de desarrollo de línea celular. Además los métodos de la invención también generan líneas celulares con concentraciones más bajas de agente de selección y amplificación que las que se pudieron alcanzar previamente. Por consiguiente, se observan niveles inferiores de marcador de selección y amplificación en las líneas celulares finales.
MX2010002003A 2007-08-20 2008-08-19 Metodo de produccion. MX2010002003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95677207P 2007-08-20 2007-08-20
PCT/EP2008/060834 WO2009024567A1 (en) 2007-08-20 2008-08-19 Production method

Publications (1)

Publication Number Publication Date
MX2010002003A true MX2010002003A (es) 2010-03-10

Family

ID=40070558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002003A MX2010002003A (es) 2007-08-20 2008-08-19 Metodo de produccion.

Country Status (13)

Country Link
US (2) US9163249B2 (es)
EP (3) EP2527367A1 (es)
JP (2) JP5592258B2 (es)
KR (1) KR101637533B1 (es)
CN (1) CN101848936B (es)
AU (1) AU2008290607B2 (es)
BR (1) BRPI0815576A2 (es)
CA (1) CA2695484C (es)
DK (1) DK3216802T3 (es)
EA (1) EA022990B1 (es)
ES (2) ES2840725T3 (es)
MX (1) MX2010002003A (es)
WO (1) WO2009024567A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527367A1 (en) * 2007-08-20 2012-11-28 Glaxo Group Limited Production method
AU2010223354A1 (en) * 2009-03-10 2011-09-08 Dsm Ip Assets B.V. Method for improving the yield of a polypeptide
EP2516664B1 (en) * 2009-12-21 2015-07-22 Pharmathene Inc. Recombinant butyrylcholinesterases and truncates thereof
WO2012001073A2 (en) 2010-07-01 2012-01-05 Glaxo Group Limited Improved method for selecting high producing cell lines
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
EP2948473A1 (en) 2013-01-24 2015-12-02 GlaxoSmithKline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
MX2018005084A (es) * 2015-11-05 2019-05-16 Bamboo Therapeutics Inc Genes de ataxia de friedreich modificados y vectores para terapia genica.
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
CA3075549A1 (en) 2017-09-13 2019-03-21 Biontech Rna Pharmaceuticals Gmbh Rna replicon for reprogramming somatic cells
AU2018333530A1 (en) 2017-09-13 2020-02-27 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
WO2021245090A1 (en) 2020-06-04 2021-12-09 BioNTech SE Rna replicon for versatile and efficient gene expression
CA3234214A1 (en) 2021-10-18 2023-04-27 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
AU2022369342A1 (en) 2021-10-18 2024-03-14 BioNTech SE Modified replicable rna and related compositions and their use
WO2023213378A1 (en) 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
EP1373547A4 (en) * 2001-03-27 2006-01-18 Smithkline Beecham Corp CONTROL OF GLYCOFORMS IN IGG
PL377769A1 (pl) * 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
WO2004046168A2 (en) * 2002-11-15 2004-06-03 The Henry M. Jackson Foundation Recombinant hiv-1 subclass d envelope glycoproteins
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US20070287163A1 (en) * 2004-05-17 2007-12-13 Crucell Holland B.V. Methods for Diagnosis of Acute Myeloid Leukemia
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AR052051A1 (es) * 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
AU2006249087B2 (en) * 2005-05-20 2012-05-17 Lonza Biologics Plc High-level expression of recombinant antibody in a mammalian host cell
AR057233A1 (es) * 2005-12-12 2007-11-21 Hoffmann La Roche Glicosilacion en la region variable
KR101263294B1 (ko) * 2006-03-30 2013-06-04 글락소 그룹 리미티드 아밀로이드­베타 펩티드에 대한 항체
MX2008012485A (es) * 2006-03-30 2008-10-10 Novartis Ag Composiciones y metodos de uso para anticuerpos de c-met.
EP2527367A1 (en) * 2007-08-20 2012-11-28 Glaxo Group Limited Production method

Also Published As

Publication number Publication date
EP2185591A1 (en) 2010-05-19
AU2008290607B2 (en) 2013-11-14
KR101637533B1 (ko) 2016-07-11
KR20100065332A (ko) 2010-06-16
DK3216802T3 (da) 2021-01-04
JP5592258B2 (ja) 2014-09-17
CA2695484A1 (en) 2009-02-26
EP2185591B1 (en) 2014-05-14
BRPI0815576A2 (pt) 2015-02-18
US9163249B2 (en) 2015-10-20
EP3216802A1 (en) 2017-09-13
EP3216802B1 (en) 2020-10-07
CA2695484C (en) 2018-05-01
US20160010111A1 (en) 2016-01-14
ES2473623T3 (es) 2014-07-07
EA201000205A1 (ru) 2011-02-28
EP2527367A1 (en) 2012-11-28
JP6029625B2 (ja) 2016-11-24
WO2009024567A1 (en) 2009-02-26
US10633673B2 (en) 2020-04-28
CN101848936B (zh) 2017-05-03
US20110040074A1 (en) 2011-02-17
EA022990B1 (ru) 2016-04-29
ES2840725T3 (es) 2021-07-07
JP2010536358A (ja) 2010-12-02
CN101848936A (zh) 2010-09-29
AU2008290607A1 (en) 2009-02-26
JP2015027298A (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
MX2010002003A (es) Metodo de produccion.
HK1247954A1 (zh) 由人類多能幹細胞產生間充質幹細胞的方法以及通過所述方法產生的間充質幹細胞
EP3539380A3 (en) Improved cell composition and methods of making the same
WO2011090726A3 (en) Use of a natural metabolite to increase crop production
WO2011130402A3 (en) Hepatocyte production by forward programming
SG196784A1 (en) Stem cell cultures
EP2307539A4 (en) METHOD FOR EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS
MX2009013706A (es) Celulas multipotentes/pluripotentes y metodos relacionados.
WO2011071476A3 (en) Compositions and methods for engineering cells
WO2009120762A3 (en) Human cardiovascular progenitor cells
IN2012DN02333A (es)
EP2434012A4 (en) VECTOR MATERIAL FOR GENERATING PLURIPOTENTAL STEM CELLS AND METHOD FOR GENERATING PLURIPOTENTAL STEM CELLS THROUGH THE VECTOR MATERIAL
WO2010078952A3 (de) Strukturierte gasdiffusionselektrode für elektrolysezellen
MX338752B (es) Metabolismo microbiano de oxianiones cloro como control de produccion de sulfuro de hidrogeno biogenico.
GB0801215D0 (en) Cell re-programming
EP2408904A4 (en) PRODUCTION OF REPROGRAMMED PLURIPOTENT CELLS
EA201390592A1 (ru) Аллели 1-d-дезоксиксилулозо-5-фосфат синтазы, ответственные за усиленный биосинтез терпенов
IN2013CN00342A (es)
MY155330A (en) Methods for salt production
AR076648A1 (es) Celulas reversiblemente inmortalizadas asi como metodos relacionados
IN2012DN00852A (es)
WO2010107285A3 (ko) 양수 내 태아 유래 중간엽줄기세포를 이용한 성장인자의 대량생산 방법
WO2009137146A3 (en) Method for producing continuous cell lines
WO2008060792A3 (en) Novel cells, compositions, and methods
HK1154032A1 (en) A process for the ultrapurification of alginates

Legal Events

Date Code Title Description
FA Abandonment or withdrawal